In biopharmaceutical research and manufacturing, established cell lines such as HEK293, CHO, and Jurkat serve as foundational tools for viral vector production, recombinant protein expression, antibody discovery, gene function studies, and drug screening.
As research programs progress toward clinical development and commercialization, cell line provenance, intellectual property (IP) ownership, and commercialization rights become increasingly important. Selecting cell lines with documented authorization and traceable origin helps establish a compliant foundation for regulatory submissions, technology transfer, and commercial manufacturing.
